Cancer treatment and research communications · 2026
Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed/refractory acute myeloid leukemia in Mexico.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De León Andrés Gómez, An Jamie Jung-Hee, Gourgioti Georgia, Xie Yanwen, Zhong Jia, Wu Eric Q, Ariza Juan Guillermo, Cheng Li-Jen
Аннотация
BACKGROUND: In Mexico, FMS-like tyrosine kinase 3 (FLT3) inhibitors have been approved for newly diagnosed or relapsed/refractory (R/R) FLT3-positive (FLT3+)acute myeloid leukemia (AML). This retrospective, physician panel-based chart review study evaluated the real-world treatment landscape, clinical outcomes, and healthcare resource utilization (HRU) in patients with FLT3+ R/R AML in Mexico.
METHODS: This retrospective, non-interventional chart review utilized de-identified data from existing charts collected from 04/26/2022-07/18/2022.
RESULTS: Of 165 patients, a phased treatment strategy (ie, an induction phase followed by consolidation and/or maintenance phase) was used in 63% of patients, with 7.3% undergoing hematopoietic stem cell transplantation (HSCT) in the first-line (1 L) setting. In the second-line (2 L) R/R setting, 18.2% received phased treatment and 4.2% underwent HSCT. Any type of complete remission (CR) was achieved in 78.1% of patients after 1 L induction; 75.8% relapsed, and 24.2% were refractory to 1 L. After 2 L induction, 79.2% of patients achieved any type of CR. Median overall survival and event-free survival were 21.7 and 13.6 months. Time to relapse after initial AML diagnosis was 13.7 months, and 10.9 months after HSCT at any line of treatment. Median time to HSCT after first diagnosis of R/R disease was not reached. HRU burden was high before and after diagnosis of R/R disease.
CONCLUSION: This is the first multi-center study conducted in Mexico among patients with FLT3+ R/R AML. Despite high remission rates following 1 L induction therapy, patients experienced disease progression and HRU remained high, indicating an unmet need. Future studies are warranted to assess how outcomes evolve with novel treatments.
GOV IDENTIFIER: Not applicable.
METHODS: This retrospective, non-interventional chart review utilized de-identified data from existing charts collected from 04/26/2022-07/18/2022.
RESULTS: Of 165 patients, a phased treatment strategy (ie, an induction phase followed by consolidation and/or maintenance phase) was used in 63% of patients, with 7.3% undergoing hematopoietic stem cell transplantation (HSCT) in the first-line (1 L) setting. In the second-line (2 L) R/R setting, 18.2% received phased treatment and 4.2% underwent HSCT. Any type of complete remission (CR) was achieved in 78.1% of patients after 1 L induction; 75.8% relapsed, and 24.2% were refractory to 1 L. After 2 L induction, 79.2% of patients achieved any type of CR. Median overall survival and event-free survival were 21.7 and 13.6 months. Time to relapse after initial AML diagnosis was 13.7 months, and 10.9 months after HSCT at any line of treatment. Median time to HSCT after first diagnosis of R/R disease was not reached. HRU burden was high before and after diagnosis of R/R disease.
CONCLUSION: This is the first multi-center study conducted in Mexico among patients with FLT3+ R/R AML. Despite high remission rates following 1 L induction therapy, patients experienced disease progression and HRU remained high, indicating an unmet need. Future studies are warranted to assess how outcomes evolve with novel treatments.
GOV IDENTIFIER: Not applicable.